MEF2D is a super-enhancer gene overexpressed in human MLL-r AML and predicts poor survival. (A) H3K27ac ChIP-seq tracks in human AML cells with or without MLL gene fusion, as well as in CD34+ normal HSPCs. Super-enhancer regions were highlighted in MLL-r cell lines. Shown are cell line names and source data accession numbers in the Gene Expression Omnibus repository. (B-C) MEF2D mRNA (B) and protein (C) expression in MLL-r and non-MLL-r human AML cell lines. (D) MEF2D expression in various human AML subgroups, comparing to the healthy bone marrow control (GSE13159). (E) qPCR analysis of MEF2D expression in primary MLL-rearranged AML samples (n = 7) and normal CD34+ bone marrow cells isolated from healthy donors (n = 6). (F) Survival analysis in The Cancer Genome Atlas (TCGA) AML patients with high or medium MEF2D expression (n = 100), comparing to those with low MEF2D expression (n = 50). ***P < .001.